Silo Pharma, Inc.

SILO

US82711P3001

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 12:21:49 2026-08-04 pm EDT			5-day change	1st Jan Change
4.480 ^USD	+3.70%		+0.45%	-12.16%

Jul. 21	Silo Pharma Advances AI Agent Platform Toward Commercial Launch And Progresses Lead PTSD Drug Program SPC-15	CI
Jul. 10	Top Midday Decliners	MT

Top Midday Decliners

Published on 07/10/2026 at 02:07 pm EDT

MT Newswires

This article is reserved for our members.

Continue with Google Continue with Apple Continue with LinkedIn

or by email

Continue with an email.

Latest news about Silo Pharma, Inc.

Jul. 21	Silo Pharma Advances AI Agent Platform Toward Commercial Launch And Progresses Lead PTSD Drug Program SPC-15	CI
Jul. 10	Top Midday Decliners	MT
Jul. 10	Silo Pharma Launches Private Placement to Raise Up to $11.7 Million	MT
Jul. 08	Silo Pharma, Inc. announced that it has received $4.000015 million in funding	CI
Jun. 29	Silo Pharma Advances SPC-15 PTSD Therapeutic With Drug-Device Robustness Study Ahead Of Planned FDA Type C Meeting Request	CI
Jun. 23	Silo Pharma, Inc. Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-In-Human Clinical Trial	CI
Jun. 23	Silo Pharma Says SPC-15 PTSD Nasal Spray Remains Stable for 9 Months	MT
Jun. 18	Silo Pharma Says it Regained Compliance With Nasdaq's Minimum Bid Price Requirement	MT
Jun. 04	Silo Pharma Shares Drop Following Implementation of 1-for-15 Reverse Stock Split	MT
May. 14	Tranche Update on Silo Pharma, Inc.'s Equity Buyback Plan announced on February 23, 2026.	CI
May. 14	Silo Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 07	Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury	CI
Apr. 29	Silo Pharma's PTSD program advances as FDA fast-tracks psychedelic therapies for PTSD	RE
Apr. 29	Silo Pharma, Inc. Announces Its PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD	CI
Apr. 21	Silo Pharma, Inc. acquired Qwikagents.com, Qikagents.ai, and Qwikagents.co from Many Ads Inc. for $0.7 million.	CI

Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Companyâ€™s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Companyâ€™s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimerâ€™s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimerâ€™s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.

Employees

Sector

Biotechnology & Medical Research

More about the company